Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia

被引：0

作者：

Mario Tiribelli

Roberto Latagliata

Luigiana Luciano

Fausto Castagnetti

Antonella Gozzini

Giovanna Rege Cambrin

Mario Annunziata

Fabio Stagno

Patrizia Pregno

Francesco Albano

Elisabetta Abruzzese

Pellegrino Musto

Enrico Montefusco

Carmen Fava

Renato Fanin

Fabrizio Pane

Gianantonio Rosti

Massimo Breccia

Giuliana Alimena

Paolo Vigneri

机构：

[1] Azienda Ospedialiero-Universitaria,Division of Hematology and Bone Marrow Transplantation

[2] Sapienza University,Department of Cellular Biotechnology and Hematology

[3] Federico II University,Hematology Department

[4] University of Bologna,Institute of Hematology L. & A. Seràgnoli

[5] University of Florence,Department of Hematology

[6] University of Torino,Department of Clinical and Biological Sciences

[7] San Luigi Hospital,Division of Hematology and Stem Cell Transplantation Unit

[8] Cardarelli Hospital,Department of Clinical and Molecular Bio

[9] University of Catania,Medicine

[10] Azienda Ospedaliera Universitaria S. Giovanni Battista,Division of Hematology

[11] University of Bari,Department of Hematology

[12] Tor Vergata University Hospital,Department of Hematology

[13] Scientific Institute of Research and Cure,Department of Hematology and Stem Cell Transplantation

[14] S. Andrea Hospital,Department of Hematology

来源：

Annals of Hematology | 2013年 / 92卷

关键词：

CML; Elderly patients; Imatinib resistance; Dasatinib; BCR-ABL mutations;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

To assess the impact of BCR-ABL kinase domain mutations on dasatinib response in elderly chronic myeloid leukemia (CML) patients, we analyzed the outcome of 76 individuals aged >60 affected by imatinib-resistant chronic-phase CML. We found that 36 cases (47 %) displayed mutations before dasatinib. Compared to non-mutated patients, subjects with point mutations had a worse response to dasatinib, with significantly lower rates of complete cytogenetic response (57 vs 32 %), higher percentage of primary resistance (16/36 vs 6/40) and a trend towards a shorter median event-free survival. Our data suggest that, in elderly patients, detection of BCR-ABL mutations negatively affects response to dasatinib.

引用

页码：179 / 183

页数：4

共 50 条

[31] Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate
E Jabbour
H Kantarjian
D Jones
M Talpaz
N Bekele
S O'Brien
X Zhou
R Luthra
G Garcia-Manero
F Giles
M B Rios
S Verstovsek
J Cortes
Leukemia, 2006, 20 : 1767 - 1773
[32] Response to dasatinib after imatinib failure according to type of preexisting BCR-ABL mutations.
Mueller, Martin C.
Erben, Philipp
Schenk, Thomas
Lauber, Stephanie
Kruth, Jens
Hoffmann, Jana
Ernst, Thomas
Lahaye, Tanja
Metzgeroth, Georgia
Acevedo, Michael
Nicaise, Claude
Hehlmann, Rudiger
Hochhaus, Andreas
BLOOD, 2006, 108 (11) : 225A - 225A
[33] Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, Hagop
Shah, Neil P.
Hochhaus, Andreas
Cortes, Jorge
Shah, Sandip
Ayala, Manuel
Moiraghi, Beatriz
Shen, Zhixiang
Mayer, Jiri
Pasquini, Ricardo
Nakamae, Hirohisa
Huguet, Francoise
Boque, Concepcion
Chuah, Charles
Bleickardt, Eric
Bradley-Garelik, M. Brigid
Zhu, Chao
Szatrowski, Ted
Shapiro, David
Baccarani, Michele
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (24): : 2260 - 2270
[34] Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
Yap, E.
Tumian, N. R.
Azma, R. Z.
Sharifah, N. A.
Salwati, S.
Hamidah, N. H.
Elias, M. H.
Wong, C. L.
MALAYSIAN JOURNAL OF PATHOLOGY, 2017, 39 (02) : 107 - 113
[35] Evaluation of BCR-ABL/ABL Ratio Increase That Corresponds to BCR-ABL Mutation In Chronic Myeloid Leukemia Patients Treated by Imatinib
Tsaur, Grigory
Ivanova, Anna
Popov, Alexander
Yakovleva, Yulia
Riger, Tatyana
Plekhanova, Olga
Ivanets, Yulia
Misyurin, Andrey
Suchkova, Marina
Shorikov, Egor
Saveliev, Leonid
Fechina, Larisa
BLOOD, 2010, 116 (21) : 1402 - 1402
[36] Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Hochhaus, Andreas
Kantarjian, Hagop M.
Baccarani, Michele
Lipton, Jeffrey H.
Apperley, Jane F.
Druker, Brian J.
Facon, Thierry
Goldberg, Stuart L.
Cervantes, Francisco
Niederwieser, Dietger
Silver, Richard T.
Stone, Richard M.
Hughes, Timothy P.
Muller, Martin C.
Ezzeddine, Rana
Countouriotis, Athena M.
Shah, Neil P.
BLOOD, 2007, 109 (06) : 2303 - 2309
[37] BCR-ABL mutations in chronic myeloid leukemia - Not only detection
Polakova, Katerina Machova
Zmekova, Vaclava
Rulcova, Jana
Klamova, Hana
Zemanova, Zuzana
Moravcova, Jana
LEUKEMIA & LYMPHOMA, 2008, 49 (08) : 1620 - 1622
[38] Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia
Carella, Angelo Michele
EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (03) : 249 - 251
[39] In patients with chronic myelogeneous leukemia (CML), response dynamics to nilotinibafter imatinib failure depend on thetype of BCR-ABL mutations
Soverini, S.
Saglio, G.
Branford, S.
Radich, J.
Kim, D. W.
Hughes, T.
Mueller, M.
Erben, P.
Hochhaus, A.
Shou, Y.
Weitzman, A.
Baccarani, M.
Martinelli, G.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 320 - 320
[40] Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation
Sigl, M.
Spoerl, S.
Schnittger, S.
Meissner, J.
Rummelt, C.
Peschel, C.
Duyster, J.
Ho, A. D.
von Bubnoff, N.
BLOOD CANCER JOURNAL, 2013, 3 : e104 - e104

← 1 2 3 4 5 →